Advances in Serodiagnostic Testing for Lyme Disease Are at Hand

John A. Branda, Barbara A. Body, Jeff Boyle, Bernard M. Branson, Raymond J. Dattwyler, Erol Fikrig, Noel J. Gerald, Maria Gomes-Solecki, Martin Kintrup, Michel Ledizet, Andrew E. Levin, Michael Lewinski, Lance A. Liotta, Adriana Marques, Paul S. Mead, Emmanuel F. Mongodin, Segaran Pillai, Prasad Rao, William H. Robinson, Kristian M. Roth & 7 others Martin E. Schriefer, Thomas Slezak, Jessica Snyder, Allen C. Steere, Jan Witkowski, Susan J. Wong, Steven E. Schutzer

Research output: Contribution to journalReview article

  • 4 Citations

Abstract

The cause of Lyme disease, Borrelia burgdorferi, was discovered in 1983. A 2-tiered testing protocol was established for serodiagnosis in 1994, involving an enzyme immunoassay (EIA) or indirect fluorescence antibody, followed (if reactive) by immunoglobulin M and immunoglobulin G Western immunoblots. These assays were prepared from whole-cell cultured B. burgdorferi, lacking key in vivo expressed antigens and expressing antigens that can bind non-Borrelia antibodies. Additional drawbacks, particular to the Western immunoblot component, include low sensitivity in early infection, technical complexity, and subjective interpretation when scored by visual examination. Nevertheless, 2-tiered testing with immunoblotting remains the benchmark for evaluation of new methods or approaches. Next-generation serologic assays, prepared with recombinant proteins or synthetic peptides, and alternative testing protocols, can now overcome or circumvent many of these past drawbacks. This article describes next-generation serodiagnostic testing for Lyme disease, focusing on methods that are currently available or near-at-hand.

LanguageEnglish (US)
Pages1133-1139
Number of pages7
JournalClinical Infectious Diseases
Volume66
Issue number7
DOIs
StatePublished - Mar 19 2018

Fingerprint

Borrelia burgdorferi
Lyme Disease
Hand
Western Blotting
Antigens
Benchmarking
Antibodies
Serologic Tests
Immunoenzyme Techniques
Recombinant Proteins
Immunoblotting
Immunoglobulin M
Cultured Cells
Immunoglobulin G
Fluorescence
Peptides
Infection
caN protocol

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Branda, J. A., Body, B. A., Boyle, J., Branson, B. M., Dattwyler, R. J., Fikrig, E., ... Schutzer, S. E. (2018). Advances in Serodiagnostic Testing for Lyme Disease Are at Hand. Clinical Infectious Diseases, 66(7), 1133-1139. https://doi.org/10.1093/cid/cix943

Advances in Serodiagnostic Testing for Lyme Disease Are at Hand. / Branda, John A.; Body, Barbara A.; Boyle, Jeff; Branson, Bernard M.; Dattwyler, Raymond J.; Fikrig, Erol; Gerald, Noel J.; Gomes-Solecki, Maria; Kintrup, Martin; Ledizet, Michel; Levin, Andrew E.; Lewinski, Michael; Liotta, Lance A.; Marques, Adriana; Mead, Paul S.; Mongodin, Emmanuel F.; Pillai, Segaran; Rao, Prasad; Robinson, William H.; Roth, Kristian M.; Schriefer, Martin E.; Slezak, Thomas; Snyder, Jessica; Steere, Allen C.; Witkowski, Jan; Wong, Susan J.; Schutzer, Steven E.

In: Clinical Infectious Diseases, Vol. 66, No. 7, 19.03.2018, p. 1133-1139.

Research output: Contribution to journalReview article

Branda, JA, Body, BA, Boyle, J, Branson, BM, Dattwyler, RJ, Fikrig, E, Gerald, NJ, Gomes-Solecki, M, Kintrup, M, Ledizet, M, Levin, AE, Lewinski, M, Liotta, LA, Marques, A, Mead, PS, Mongodin, EF, Pillai, S, Rao, P, Robinson, WH, Roth, KM, Schriefer, ME, Slezak, T, Snyder, J, Steere, AC, Witkowski, J, Wong, SJ & Schutzer, SE 2018, 'Advances in Serodiagnostic Testing for Lyme Disease Are at Hand' Clinical Infectious Diseases, vol. 66, no. 7, pp. 1133-1139. https://doi.org/10.1093/cid/cix943
Branda JA, Body BA, Boyle J, Branson BM, Dattwyler RJ, Fikrig E et al. Advances in Serodiagnostic Testing for Lyme Disease Are at Hand. Clinical Infectious Diseases. 2018 Mar 19;66(7):1133-1139. https://doi.org/10.1093/cid/cix943
Branda, John A. ; Body, Barbara A. ; Boyle, Jeff ; Branson, Bernard M. ; Dattwyler, Raymond J. ; Fikrig, Erol ; Gerald, Noel J. ; Gomes-Solecki, Maria ; Kintrup, Martin ; Ledizet, Michel ; Levin, Andrew E. ; Lewinski, Michael ; Liotta, Lance A. ; Marques, Adriana ; Mead, Paul S. ; Mongodin, Emmanuel F. ; Pillai, Segaran ; Rao, Prasad ; Robinson, William H. ; Roth, Kristian M. ; Schriefer, Martin E. ; Slezak, Thomas ; Snyder, Jessica ; Steere, Allen C. ; Witkowski, Jan ; Wong, Susan J. ; Schutzer, Steven E. / Advances in Serodiagnostic Testing for Lyme Disease Are at Hand. In: Clinical Infectious Diseases. 2018 ; Vol. 66, No. 7. pp. 1133-1139.
@article{fd64bdf57b154568960c7aa8f94870fd,
title = "Advances in Serodiagnostic Testing for Lyme Disease Are at Hand",
abstract = "The cause of Lyme disease, Borrelia burgdorferi, was discovered in 1983. A 2-tiered testing protocol was established for serodiagnosis in 1994, involving an enzyme immunoassay (EIA) or indirect fluorescence antibody, followed (if reactive) by immunoglobulin M and immunoglobulin G Western immunoblots. These assays were prepared from whole-cell cultured B. burgdorferi, lacking key in vivo expressed antigens and expressing antigens that can bind non-Borrelia antibodies. Additional drawbacks, particular to the Western immunoblot component, include low sensitivity in early infection, technical complexity, and subjective interpretation when scored by visual examination. Nevertheless, 2-tiered testing with immunoblotting remains the benchmark for evaluation of new methods or approaches. Next-generation serologic assays, prepared with recombinant proteins or synthetic peptides, and alternative testing protocols, can now overcome or circumvent many of these past drawbacks. This article describes next-generation serodiagnostic testing for Lyme disease, focusing on methods that are currently available or near-at-hand.",
author = "Branda, {John A.} and Body, {Barbara A.} and Jeff Boyle and Branson, {Bernard M.} and Dattwyler, {Raymond J.} and Erol Fikrig and Gerald, {Noel J.} and Maria Gomes-Solecki and Martin Kintrup and Michel Ledizet and Levin, {Andrew E.} and Michael Lewinski and Liotta, {Lance A.} and Adriana Marques and Mead, {Paul S.} and Mongodin, {Emmanuel F.} and Segaran Pillai and Prasad Rao and Robinson, {William H.} and Roth, {Kristian M.} and Schriefer, {Martin E.} and Thomas Slezak and Jessica Snyder and Steere, {Allen C.} and Jan Witkowski and Wong, {Susan J.} and Schutzer, {Steven E.}",
year = "2018",
month = "3",
day = "19",
doi = "10.1093/cid/cix943",
language = "English (US)",
volume = "66",
pages = "1133--1139",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Advances in Serodiagnostic Testing for Lyme Disease Are at Hand

AU - Branda, John A.

AU - Body, Barbara A.

AU - Boyle, Jeff

AU - Branson, Bernard M.

AU - Dattwyler, Raymond J.

AU - Fikrig, Erol

AU - Gerald, Noel J.

AU - Gomes-Solecki, Maria

AU - Kintrup, Martin

AU - Ledizet, Michel

AU - Levin, Andrew E.

AU - Lewinski, Michael

AU - Liotta, Lance A.

AU - Marques, Adriana

AU - Mead, Paul S.

AU - Mongodin, Emmanuel F.

AU - Pillai, Segaran

AU - Rao, Prasad

AU - Robinson, William H.

AU - Roth, Kristian M.

AU - Schriefer, Martin E.

AU - Slezak, Thomas

AU - Snyder, Jessica

AU - Steere, Allen C.

AU - Witkowski, Jan

AU - Wong, Susan J.

AU - Schutzer, Steven E.

PY - 2018/3/19

Y1 - 2018/3/19

N2 - The cause of Lyme disease, Borrelia burgdorferi, was discovered in 1983. A 2-tiered testing protocol was established for serodiagnosis in 1994, involving an enzyme immunoassay (EIA) or indirect fluorescence antibody, followed (if reactive) by immunoglobulin M and immunoglobulin G Western immunoblots. These assays were prepared from whole-cell cultured B. burgdorferi, lacking key in vivo expressed antigens and expressing antigens that can bind non-Borrelia antibodies. Additional drawbacks, particular to the Western immunoblot component, include low sensitivity in early infection, technical complexity, and subjective interpretation when scored by visual examination. Nevertheless, 2-tiered testing with immunoblotting remains the benchmark for evaluation of new methods or approaches. Next-generation serologic assays, prepared with recombinant proteins or synthetic peptides, and alternative testing protocols, can now overcome or circumvent many of these past drawbacks. This article describes next-generation serodiagnostic testing for Lyme disease, focusing on methods that are currently available or near-at-hand.

AB - The cause of Lyme disease, Borrelia burgdorferi, was discovered in 1983. A 2-tiered testing protocol was established for serodiagnosis in 1994, involving an enzyme immunoassay (EIA) or indirect fluorescence antibody, followed (if reactive) by immunoglobulin M and immunoglobulin G Western immunoblots. These assays were prepared from whole-cell cultured B. burgdorferi, lacking key in vivo expressed antigens and expressing antigens that can bind non-Borrelia antibodies. Additional drawbacks, particular to the Western immunoblot component, include low sensitivity in early infection, technical complexity, and subjective interpretation when scored by visual examination. Nevertheless, 2-tiered testing with immunoblotting remains the benchmark for evaluation of new methods or approaches. Next-generation serologic assays, prepared with recombinant proteins or synthetic peptides, and alternative testing protocols, can now overcome or circumvent many of these past drawbacks. This article describes next-generation serodiagnostic testing for Lyme disease, focusing on methods that are currently available or near-at-hand.

UR - http://www.scopus.com/inward/record.url?scp=85044243912&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044243912&partnerID=8YFLogxK

U2 - 10.1093/cid/cix943

DO - 10.1093/cid/cix943

M3 - Review article

VL - 66

SP - 1133

EP - 1139

JO - Clinical Infectious Diseases

T2 - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 7

ER -